NASDAQ:UTHR - United Therapeutics Stock Price, Price Target & More

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

United Therapeutics declared that its Board of Directors has authorized a stock buyback plan on Sunday, June 4th 2017, which authorizes the company to repurchase $250,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 4.6% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company's board believes its shares are undervalued.

United Therapeutics Co. (NASDAQ:UTHR) posted its quarterly earnings data on Wednesday, May, 2nd. The biotechnology company reported $5.57 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $3.62 by $1.95. The biotechnology company had revenue of $389.20 million for the quarter, compared to analysts' expectations of $393.96 million. United Therapeutics had a net margin of 27.74% and a return on equity of 26.68%. The company's revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the firm posted $3.61 earnings per share. View United Therapeutics' Earnings History.

United Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for United Therapeutics.

6 analysts have issued twelve-month target prices for United Therapeutics' stock. Their predictions range from $95.00 to $232.00. On average, they anticipate United Therapeutics' share price to reach $139.6667 in the next twelve months. This suggests a possible upside of 11.7% from the stock's current price. View Analyst Ratings for United Therapeutics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to United Therapeutics include Mylan (MYL), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), Genmab A/S (GNMSF), Perrigo (PRGO), Beigene (BGNE), Sarepta Therapeutics (SRPT), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals (VRX) and SAGE Therapeutics (SAGE).

Media stories about UTHR stock have been trending somewhat positive on Sunday, Accern reports. Accern identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. United Therapeutics earned a media sentiment score of 0.22 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 46.73 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

United Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include NN Investment Partners Holdings N.V. (0.21%), Bank of Montreal Can (0.15%), Retirement Systems of Alabama (0.13%), James Investment Research Inc. (0.05%), Empirical Finance LLC (0.04%) and Fjarde AP Fonden Fourth Swedish National Pension Fund (0.03%). Company insiders that own United Therapeutics stock include Christopher Causey, Christopher Patusky, Judy D Olian, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Institutional Ownership Trends for United Therapeutics.

UTHR stock was sold by a variety of institutional investors in the last quarter, including Empirical Finance LLC, NN Investment Partners Holdings N.V., Municipal Employees Retirement System of Michigan, RDL Financial Inc. and Xact Kapitalforvaltning AB. Company insiders that have sold United Therapeutics company stock in the last year include Christopher Causey, Judy D Olian, Martine A Rothblatt and Raymond Dwek. View Insider Buying and Selling for United Therapeutics.

UTHR stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can, James Investment Research Inc., Nisa Investment Advisors LLC, Clinton Group Inc., Assenagon Asset Management S.A., Fox Run Management L.L.C., Fjarde AP Fonden Fourth Swedish National Pension Fund and State of Alaska Department of Revenue. View Insider Buying and Selling for United Therapeutics.

Shares of UTHR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of UTHR stock can currently be purchased for approximately $125.03.

United Therapeutics has a market capitalization of $5.44 billion and generates $1.73 billion in revenue each year. The biotechnology company earns $417.90 million in net income (profit) each year or $10.89 on an earnings per share basis. United Therapeutics employs 800 workers across the globe.

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company can be reached via phone at 301-608-9292 or via email at [email protected]